Epigenetically programmed resistance to chemo- and immuno-therapies.

2区 医学 Q1 Medicine
Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-01-27 DOI:10.1016/bs.acr.2022.12.001
Reddick R Walker, Zainab Rentia, Katherine B Chiappinelli
{"title":"Epigenetically programmed resistance to chemo- and immuno-therapies.","authors":"Reddick R Walker,&nbsp;Zainab Rentia,&nbsp;Katherine B Chiappinelli","doi":"10.1016/bs.acr.2022.12.001","DOIUrl":null,"url":null,"abstract":"<p><p>Resistance to cancer treatments remains a major barrier in developing cancer cures. While promising combination chemotherapy treatments and novel immunotherapies have improved patient outcomes, resistance to these treatments remains poorly understood. New insights into the dysregulation of the epigenome show how it promotes tumor growth and resistance to therapy. By altering control of gene expression, tumor cells can evade immune cell recognition, ignore apoptotic cues, and reverse DNA damage induced by chemotherapies. In this chapter, we summarize the data on epigenetic remodeling during cancer progression and treatment that enable cancer cell survival and describe how these epigenetic changes are being targeted clinically to overcome resistance.</p>","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"158 ","pages":"41-71"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184181/pdf/nihms-1897571.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.acr.2022.12.001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Resistance to cancer treatments remains a major barrier in developing cancer cures. While promising combination chemotherapy treatments and novel immunotherapies have improved patient outcomes, resistance to these treatments remains poorly understood. New insights into the dysregulation of the epigenome show how it promotes tumor growth and resistance to therapy. By altering control of gene expression, tumor cells can evade immune cell recognition, ignore apoptotic cues, and reverse DNA damage induced by chemotherapies. In this chapter, we summarize the data on epigenetic remodeling during cancer progression and treatment that enable cancer cell survival and describe how these epigenetic changes are being targeted clinically to overcome resistance.

对化疗和免疫疗法的表观遗传学程序性耐药性。
对癌症治疗的耐药性仍然是开发癌症治疗方法的主要障碍。尽管有希望的联合化疗和新型免疫疗法改善了患者的预后,但对这些治疗的耐药性仍知之甚少。对表观基因组失调的新见解显示了它如何促进肿瘤生长和对治疗的耐药性。通过改变基因表达的控制,肿瘤细胞可以逃避免疫细胞的识别,忽略凋亡线索,并逆转化疗诱导的DNA损伤。在本章中,我们总结了癌症进展和治疗过程中表观遗传学重塑的数据,这些数据使癌症细胞存活,并描述了这些表观遗传学变化如何在临床上被靶向以克服耐药性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Cancer Research
Advances in Cancer Research 医学-肿瘤学
CiteScore
10.00
自引率
0.00%
发文量
52
期刊介绍: Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. The first ACR volume came out in the year that Watson and Crick reported on the central dogma of biology, the DNA double helix. In the first 100 volumes are found many contributions by some of those who helped shape the revolution and who made many of the remarkable discoveries in cancer research that have developed from it.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信